Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509677 | 0.87 | GRM2 (0.49) | SMN1; SMN2PIK3CD | |
| SCHEMBL13573037 | 0.87 | GRM2 (0.49) | SMN1; SMN2PIK3CD | |
| SCHEMBL8292105 | 0.85 | ALDH1A1 (0.49) | PIK3CDLMNA | |
| SCHEMBL12169472 | 0.85 | PIK3CD (0.50) | KCNH2PIK3CDKMT2A | |
| SCHEMBL12015723 | 0.85 | PIK3CD (0.50) | KCNH2PIK3CDKMT2A | |
| SCHEMBL9424540 | 0.85 | PIK3CD (0.50) | KCNH2PIK3CDKMT2A | |
| SCHEMBL16874589 | 0.82 | KCNH2 (0.54) | KCNH2SMN1; SMN2LMNAGRIN2B | |
| SCHEMBL16874550 | 0.82 | KCNH2 (0.51) | KCNH2SMN1; SMN2TP53LMNAKMT2A | |
| SCHEMBL31110446 | 0.82 | KCNH2 (0.54) | KCNH2SMN1; SMN2LMNAGRIN2B | |
| SCHEMBL16874593 | 0.82 | KCNH2 (0.54) | KCNH2SMN1; SMN2LMNAGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180110766-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170258777-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885SMN1; SMN2 322/4885PIK3CD 2682/4885 |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885SMN1; SMN2 322/4885PIK3CD 2682/4885 |
| US-20170258777-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885SMN1; SMN2 322/4885PIK3CD 2682/4885 |
| US-20180110766-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885SMN1; SMN2 322/4885PIK3CD 2682/4885 |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885SMN1; SMN2 322/4885PIK3CD 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.